Estée Lauder (NYSE:EL) beat Q3 earnings expectations with strong margin gains and updated its FY25 outlook. However, weakness in Asia travel retail and North America led to a price target cut to $66, per Telsey Advisory Group.
Beauty products company Estée Lauder (NYSE:EL) announced better-than-expected revenue in Q1 CY2025, but sales fell by 9.9% year on year to $3.55 billion. Its non-GAAP profit of $0.65 per share was significantly above analysts’ consensus estimates.
Estée Lauder is currently considered a high-risk stock. The brand is iconic, but it’s facing real challenges—weak sales in China, a botched acquisition, rising debt, and a stock price that’s dropped over 83% from its peak.
The end of an earnings season can be a great time to discover new stocks and assess how companies are handling the current business environment. Let’s take a look at how Olaplex (NASDAQ:OLPX) and the rest of the personal care stocks fared in Q4.
Wrapping up Q4 earnings, we look at the numbers and key takeaways for the personal care stocks, including Nature's Sunshine (NASDAQ:NATR) and its peers.
As the Q4 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the personal care industry, including Nu Skin (NYSE:NUS) and its peers.
Stay tuned for the market movements in the S&P500 index on Monday. Check out the gap up and gap down stocks in the S&P500 index during today's session.
Estée Lauder has gotten torched over the last six months - since October 2024, its stock price has dropped 41.8% to $55.23 per share. This might have investors contemplating their next move.
Earnings results often indicate what direction a company will take in the months ahead. With Q4 behind us, let’s have a look at Estée Lauder (NYSE:EL) and its peers.
Retailers and consumer-facing companies are reeling more prominently as they fear the potential hike to consumer prices of their products will directly hurt sales.
